Jan 15, 2026 08:17AM Hoth Therapeutics receives positive EU regulatory decision for HT-001 trial

Jan 2, 2026 08:14AM Hoth Therapeutics files two patents for cancer skin toxicity treatments

Nov 20, 2025 08:13AM Hoth Therapeutics joins NVIDIA Connect program for AI computing resources

Nov 17, 2025 06:03AM Hoth Therapeutics Inc. (HOTH) files $50M mixed shelf

Oct 27, 2025 07:49AM Hoth Therapeutics begins VA study of GDNF therapy for obesity

Oct 21, 2025 08:23AM Hoth Therapeutics receives FDA orphan drug status for HT-KIT cancer drug

Oct 8, 2025 08:03AM Hoth Therapeutics secures NVIDIA AI Enterprise licenses for drug research

Sep 24, 2025 08:14AM Hoth Therapeutics files patents for HT-001 in new dermatology indications

Sep 16, 2025 08:16AM Hoth Therapeutics submits European trial application, adds crypto to treasury

Sep 10, 2025 08:29AM Hoth Therapeutics submits European trial application for HT-001 treatment

Sep 4, 2025 08:20AM Hoth Therapeutics adopts Lantern Pharma's AI tool for drug development

Sep 2, 2025 08:16AM Hoth Therapeutics reports preclinical results for cancer drug HT-KIT

Jul 29, 2025 07:58AM Hoth Therapeutics partners with ICON to expand HT-001 trial to Europe

Jul 22, 2025 08:19AM Hoth Therapeutics partners with VA for obesity therapy study

Jun 25, 2025 08:38AM Silo Pharma (SILO) Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025 08:29AM Hoth Therapeutics Inc. (HOTH) and Silo Pharma (SILO) form a 50/50 JV to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs

Jun 24, 2025 10:36AM Hoth Therapeutics Inc. (HOTH) HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 18, 2025 01:35PM Hoth Therapeutics (HOTH) Regains Nasdaq Compliance

Jun 18, 2025 08:22AM Hoth Therapeutics (HOTH) Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 12, 2025 09:17AM Hoth Therapeutics Inc. (HOTH) Secures Japanese Patent for HT-KIT Platform

Jun 11, 2025 08:28AM Hoth Therapeutics (HOTH) Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 5, 2025 08:13AM Hoth Therapeutics (HOTH) to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

May 12, 2025 07:31AM Hoth Therapeutics Inc. (HOTH) Reports Positive Preclinical Results for HT-KIT

Apr 17, 2025 08:02AM Hoth Therapeutics (HOTH) Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 15, 2025 08:19AM Hoth Therapeutics Inc. (HOTH) Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 2, 2025 07:58AM Hoth Therapeutics Inc. (HOTH) Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease

Mar 31, 2025 04:45PM Hoth Therapeutics Inc. (HOTH) Receives USPTO Filing Receipt for HT-001

Mar 26, 2025 08:02AM Hoth Therapeutics Inc. (HOTH) Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 18, 2025 08:07AM Hoth Therapeutics Inc. (HOTH) Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors

Mar 10, 2025 08:03AM Hoth Therapeutics Inc. (HOTH) to Submit Expanded Access Application for HT-001

Mar 5, 2025 01:40PM Hoth Therapeutics Inc. (HOTH) Announces Positive Results for HT-001

Mar 4, 2025 08:16AM Hoth Therapeutics (HOTH) Reports Positive Findings on GDNF's Potential

Feb 10, 2025 08:22AM Hoth Therapeutics (HOTH) Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Jan 21, 2025 08:30AM Hoth Therapeutics (HOTH) Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Jan 8, 2025 01:28PM Hoth Therapeutics Inc. (HOTH) Responds to Market Rumors and Shareholder Inquiries

Jan 7, 2025 08:29AM Hoth Therapeutics Inc. (HOTH) Reports HT-001 Delivered 100% Success in Combating Cancer Treatment Skin Toxicities

Dec 26, 2024 07:59AM Hoth Therapeutics (HOTH) Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Nov 20, 2024 07:39AM Hoth Therapeutics Inc. (HOTH) Approves Bitcoin as Treasury Reserve Asset

Nov 4, 2024 06:49AM H.C. Wainwright Reiterates Buy Rating on Hoth Therapeutics (HOTH)

Oct 29, 2024 12:44PM Hoth Therapeutics (HOTH) Issues an Update on Cancer Therapeutic HT-KIT Results

Oct 16, 2024 06:57AM H.C. Wainwright Reiterates Buy Rating on Hoth Therapeutics (HOTH)

Oct 15, 2024 06:40AM Hoth Therapeutics (HOTH) Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Oct 11, 2024 06:50AM Benchmark Reiterates Speculative Buy Rating on Hoth Therapeutics (HOTH)

Sep 5, 2024 08:06AM Hoth Therapeutics (HOTH) Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Aug 21, 2024 08:19AM EF Hutton Assumes Hoth Therapeutics (HOTH) at Buy

Aug 15, 2024 08:04AM Hoth Therapeutics (HOTH) and Aronnax Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Jul 24, 2024 06:31AM Hoth Therapeutics Inc. (HOTH) Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Jul 16, 2024 08:32AM Hoth Therapeutics (HOTH) Expands Clinical Trial for Cancer Patients

Jun 10, 2024 07:11AM Hoth Therapeutics (HOTH) Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery